Lymphoplasmacytic lymphoma associated with diffuse large B-cell lymphoma: Progression or divergent evolution?

Macarena Boiza-Sánchez¹, Rebeca Manso¹, Olga Balagué², Cristina Chamizo¹, Elham Askari³, Rocio Nieves Salgado⁴, Carlos Blas-López⁴, Elena Aguirregoicoa-García¹, Javier Menárguez⁵, Carlos Santonja¹, Magdalena Adrados⁶, Miguel Ángel Limeres-González⁵, Miguel Ángel Piris¹, Socorro María Rodríguez-Pinilla¹*

¹ Pathology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ² Pathology Department, Hospital Clinic, Barcelona, Spain, ³ Hematology Department, Hospital Universitario, Madrid, Spain, ⁴ Cytogenetics Service, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ⁵ Pathology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain, ⁶ Pathology Department, Hospital Universitario de la Princesa, Madrid, Spain, ⁷ Pathology Department, Hospital Universitario de Gran Canaria “Doctor. Negrín”, Las Palmas de Gran Canaria, Spain

* smrodriguez@fdj.es

Abstract

Aim

Lymphoplasmacytic lymphoma (LPL) is an indolent mature B-cell-neoplasm with involvement of the bone marrow. At least 90% of LPLs carry MYD88-L265P mutation and some of them (~10%) transform into diffuse large B-cell-lymphoma (DLBCL).

Material and methods

Over the past 15 years we have collected 7 cases where the both LPL and DLBCL were diagnosed in the same patient. Clinical records, analytical data and histopathological specimens were reviewed. FISH studies on paraffin-embedded tissue for MYC, BCL2 and BCL6 genes were performed, as well as MYD88-L265P mutation and IGH rearrangement analysis by PCR. A mutational study was done by massive next generation sequencing (NGS).

Results

There were 4 women and 3 men between 36–91 years of age. Diagnoses were made simultaneously in 4 patients. In two cases the LPL appeared before the DLBCL and in the remaining case the high-grade component was discovered 5 years before the LPL. In 6 cases both samples shared the MYD88-L265P mutation. IGH rearrangement analysis showed overlapping features in two of 6 cases tested. Mutational study was evaluable in three cases for both samples showing shared and divergent mutations.

Conclusions

These data suggest different mechanisms of DLBCL development in LPL patients.
Introduction

Lymphoplasmacytic lymphoma (LPL) is a low-grade B-cell lymphoma (LGBL) composed of B cells at different differentiation stages, consisting of small lymphocytes, plasmacytoid lymphocytes, and plasma cells, not fulfilling criteria for any other small B-cell lymphoid neoplasm. Bone marrow (BM) is usually involved followed in frequency by lymph nodes and spleen. Most patients are clinically diagnosed with Waldenström macroglobulinemia (WM), which is defined as LPL with 10% or more BM involvement and an immunoglobulin M (IgM) monoclonal gammopathy of any concentration. The cause of WM remains unknown although a role for genetic, immune-related, and environmental factors has been suggested [1–3]. Next-generation sequencing studies in WM have identified multiple recurring somatic mutations, including MYD88-L265P (up to 97%), CXCR4 (30%-40%), ARID1A (17%), and CD79B (8%-15%) [3, 4]. Although MYD88-L265P mutation seemed to be very characteristic of this disease, it has also been described in other LGBLs with lower frequency, namely in MZL (6%-10%) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (3% to 8%) [5].

More than 10% of WMs transform into more aggressive disorders, such as diffuse large B-cell lymphoma (DLBCL) and their prognosis appears to be worse than that for patients with de novo DLBCL, with survival from the time of transformation of about 2 years [6, 7]. Transformation to DLBCL can occur at any time point along the course of WM, i.e. at diagnosis, before treatment, during therapy and even 20 years after the initial diagnosis. Interestingly, this secondary DLBCL can be either clonally or not clonally related to the WM neoplasm [6–8]. These facts make the distinction between progression of a low-grade B-cell lymphoma and the development of a second primary aggressive tumor sometimes challenging.

We identified 7 patients diagnosed with both LPL and DLBCL. Clinical data and molecular features of all these cases were heterogeneous. Interestingly, all cases but one showed the MYD88-L265P mutation in both neoplastic components. The significance of this finding in the development of both LPL and DLBCL is discussed.

Material and methods

Patient samples

Seven formalin-fixed, paraffin-embedded (FFPE) samples were retrieved from the Biobank of Fundación Jiménez Díaz (Madrid, Spain). All patients gave informed consent to be included in this study, being their data anonymized. Diagnoses were established according to the WHO classification [9]. Patients’ diagnosis, medical management and follow up was done between years 2000–2019.

The Comité de Ética de la Investigación de la Fundación Jiménez Díaz, CEIm-FJD approved the study “Linfomas agresivos, análisis clínico y genómico para una medicina de precisión (B2017/BMD-3778. LINFOMAS CM. CI: PIC75-018)” in which this study is included.

DNA and RNA extraction

We extracted genomic DNA (DNAg) and RNA of tumoral FFPE samples using a RecoverAll™ Multi-Sample RNA/DNA (Invitrogen, Carlsbad, CA, USA) in accordance with the manufacturer’s protocol. DNAs and RNAs were quantified with Qubit® (Invitrogen, Carlsbad, CA, USA).

PCR for IgH gene rearrangement

PCR was performed to analyze the clonal expansion of B-cells. DNA was extracted from paraffin sections and B-cell clonal expansion was detected by PCR for the immunoglobulin heavy
IGH, VH—JH and DH—JH) chain gene rearrangement [10] (S1 Table). Appropriate positive and negative controls were included in all experiments. Clonality was assayed following well-established recommendations [11].

**qPCR detection of MYD88-L265P mutation**

To identify the presence of the MYD88 mutation, we used the primers described by Jiménez et al. [12] and quantitative PCR (qPCR) based in allelic discrimination (S2 Table). Triplicates were performed on a Light Cycler 480 Real-Time PCR System (Roche, Basel, Switzerland). Assays were run in 384-well plates in a reaction volume of 10 μl, using 50 ng of genomic DNA (gDNA), 5 μl of Light Cycler 480 Probes Master, 0.15 μl primer (20μM, wild type or mutated) and 0.1μl probe (20μM). The reaction mixture was incubated at 95°C for 10 min, followed by 45 cycles of amplification at 95°C for 10 s and 60°C for 30 s. The data were analyzed with software Light Cycler 480 SW 1.5 (Roche) using the ΔCp method. Cp values were analyzed and showed a standard deviation minor of 0.25. Cases with a Cp value >20 were considered wild type.

**Mutation with the TruSeq custom amplicon**

Dual-strand sequencing eliminates false-positive C-T mutations that can arise from deamination events during formalin fixation. The probes for this custom panel were designed with DesignStudio (Illumina, San Diego, CA, USA) and consisted of 1399 amplicons with an average size of 175 bp and a cumulative targeted region of 140 kb [13]. Polymorphisms were avoided in the design of the primers. The target genes are listed in S3 Table.

Target enrichment was performed in FFPET-extracted DNA according to manufacturer’s instructions (TruSeq Amplicon—Cancer Panel Library Preparation Guide; January 2017; Illumina). The total amount of input DNA ranged from 30 to 100ng. After library preparation, indexing and bead purification, the libraries (two libraries per sample, one per strand) were quantified by Qubit™ (Invitrogen, Carlsbad, CA, USA) and then normalized with beads and pooled for sequencing. The pooled libraries were sequenced with a MiSeq Reagent Kit V2 (paired-end, 2x151) on a MiSeq instrument (Illumina, San Diego, CA, USA), as described in the manufacturer’s protocol.

**Mutation with Oncomine Comprehensive Assay (OCA)**

The Oncomine Comprehensive Assay, OCA (Ion Torrent, ThermoFisher Scientific, Waltham, Massachusetts, USA) was used to validate common data. The DNA/RNA libraries were performed according to manufacturer’s instructions (OncomineTM Comprehensive Assay v3 Guide; ThermoFisher Scientific, Waltham, Massachusetts, USA). DNA libraries were generated from 20 ng of DNA using the Ion AmpliSeq Library Kit 2.0 (Life Technologies, Carlsbad, CA, USA) and the OCP AmpliSeq panel according to the manufacturer’s instructions with barcode incorporation. RNA libraries were generated from 15 ng of RNA using the Ion AmpliSeq RNA Library Kit. Templates for DNA and RNA libraries were prepared using the Ion AmpliSeq™ Library Preparation the Ion 540™ Chef system (Life Technologies, Carlsbad, CA, USA) on the Ion Chef according to the manufacturer’s instructions. Sequencing of multiplexed templates was performed using the Ion Torrent S5 on Ion 540 chips (Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions.

**Bioinformatic analysis**

The sequences were aligned with the reference genome NCBI Build 37 (UCSC hg19). Variants were then identified by the Variant Caller algorithm and the annotation of variants was
performed with the Ion Reporter (Life Technologies, Carlsbad, CA, USA) and Variant Interpreter (Illumina, San Diego, CA, USA). We mapped reads to the hg19 reference genome using the Integrated Genome Viewer (IGV v2.3; Broad Institute, Cambridge, MA, USA). The Catalogue of Somatic Mutations in Cancer (COSMIC), the National Center for Biotechnology ClinVar and cBioPortal for Cancer Genomics database were checked to identify pathogenetic changes. In addition, the variants were analysed with two mutational functional prediction programs (SIFT and POLYPHEN-2).

Immunohistochemistry

FFPE sections from both LPL and DLBCL samples of all patients were stained by the EndVision method with a heat-induced antigen-retrieval step for a panel of 13 different antibodies (S4 Table). Reactive tonsil tissue was included as a control. The primary antibodies were omitted to provide negative controls.

Results

Over the past 15 years 7 patients were identified with diagnoses of both LPL and DLBCL. Here we have compared the clinical, histological and molecular data of both tumours in this series of patients in an effort to unveil the mechanism of tumour progression.

Clinical features

There were 4 women and 3 men, with ages between 36 and 91 years (mean 61 years). Four patients (57%) showed B symptoms (fever, night sweats and weight loss) as early manifestations, and 28% experienced bone pain. Less frequent symptoms were fatigue and dysphagia or hemorrhagic stroke (each 14%). One patient showed multiple asymptomatic enlarged lymph nodes.

Monoclonal paraproteinemia (IgM) was found at diagnosis in all of them and cryoglobulinemia was detected in one case (Table 1).

Table 1. Clinical data of our series of patients (DOD: Dead of disease; DOC: Dead of other cause; CR: Complete response; DLBCL: Diffuse large B-cell-lympoma; LPL: Lymphoplasmacytic lymphoma).

| CASE 1 | CASE 2 | CASE 3 | CASE 4 | CASE 5 | CASE 6 | CASE 7 |
|--------|--------|--------|--------|--------|--------|--------|
| Clinical features | B symptoms Bone pain | B symptoms | Asymptomatic adenopathies | Hemorrhagic stroke | B symptoms Bone pain | Fatigue B symptoms | Dysphagia Nasal congestion |
| Blood/urine test | IgM 1066 mg/dl M-protein IgM κ Hb 9,1 g/dl | IgM 1940 mg/dl M-protein IgM κ Hb 13,9 g/dl | IgM 325 mg/dl M-protein IgM κ Hb 8,9 g/dl Cryoglobulinemia | IgM 1780 mg/dl M-protein IgM κ Hb 12,8 g/dl | IgM 3063 mg/dl M-protein IgM κ Hb 8,5 g/dl | IgM 2025 mg/dl M-protein IgM κ Hb 8,1 g/dl | IgM 1654 mg/dl M-protein IgM κ Hb 13,7 g/dl |
| First diagnosis Location/ Tumour Type | Bone marrow LPL | Adenopathies + Bone Marrow non-GC DLBCL + LPL, respectively | Multiple adenopathies non-GC DLBCL | CNS non-GC DLBCL | Pelvic adenopathies LPL | Adenopathies+BM Pancreatic & renal involvement non-GC DLBCL | Pharyngeal mass Adenopathies non-GC DLBCL |
| Treatment | CDR x6 | R-CHOP | NA | NA | NA | R-CHOP x3 | NA |
| Second diagnosis Location/ Tumour type | Mandibular mass + Adenopathies DLBCL ABC | CNS (relapse) non-GC DLBCL | Bone marrow LPL | Adenopathies + Bone marrow LPL | Bone marrow non-GC DLBCL + LPL | Cavity mass + Bone marrow LPL | Bone marrow LPL |
| 2° Treatment | R-CHOP x6 | MTX/RITUXIMAB | R-CHOP + RCD | MTX/RITUXIMAB | R-CHOP x1 | RITUX/BENDA | R-CHOP x6 |
| Current state | DLBCL: CR LPL: relapse BM | DLBCL: CR M-protein persists DOC (craneal trauma) | DLBCL: CR LPL: minimum marrow infiltrate | DLBCL: CR LPL: PR (stable disease) | DOC (severe reaction to Rituximab) | DLBCL: CR LPL: PR (stable disease) | DOD (clinical progression) |

https://doi.org/10.1371/journal.pone.0241634.t001
In one case the DLBCL preceded the LPL (case 6), with an interval of 5 years. In four cases both lymphoma types were simultaneously diagnosed (cases 2, 3, 4 and 7), although in case 4; the DLBCL was diagnosed two months earlier than the LPL lymphoma. In another two cases the diagnosis of LPL preceded the diagnosis of DLBCL after 3 and 1 year, respectively (case 1 and 5).

Lymphoplasmacytic lymphoma was diagnosed in bone marrow (4 cases), lymph node (2 cases) or cavum (one case), although all 7 cases showed bone marrow infiltration. In the histological findings, one case had predominance of plasmacytoid cellularity (with numerous Dutcher and Russell bodies) and another case showed a predominance of mature B cells. The other cases had mixed cellularity.

Four of the DLBCL cases were diagnosed on lymph nodes, one in central nervous system, one in bone marrow and one in Waldeyer’s ring. Additionally, one patient showed pancreatic and renal involvement.

All patients received treatment. R-CHOP was the most frequently applied chemotherapy regimen (86%), usually with completion of 6 cycles. One patient died after the first cycle due to a severe reaction to Rituximab. Two patients received R-CHOP in combination with either Bendamustine-Rituximab or Methotrexate-Rituximab. Only one patient received exclusively chemotherapy with Methotrexate-Rituximab.

The outcome was favorable in 4 cases (57%), with complete response of the high-grade component and stable disease of the LPL component (minimum marrow infiltrate). One of these cases (Case 1) suffered a bone marrow relapse three years after stabilization of the LPL and remitted after Ibrutinib treatment. Three patients died; one from traumatic brain injury, one due to Rituximab toxicity, and one from disease progression (Case 7); the latter was the only case with no MYD88-L265P mutation shared by both samples.

Immunohistochemical features

Two of the LPL cases expressed p53 (Cases 1 and 5) and one was CD10 positive (Case 6) (Fig 1). All cases expressed IgM with kappa light chain restriction, with the exception of Case 2 that was lambda.

According to Hans’s algorithm, all DLBCL cases were considered of non-germinal center B-cell phenotype (non-GCB) (Fig 2).

There were CD10 negative, MUM1 positive. None of the cases were EBV (EBER) positive. Three of them were p53-positive (Cases 1, 5 and 7). Cases 1 and 5 developed two and one years
after the diagnosis of LPL, respectively and p53 was also present in the LPL component from the beginning of the disease.

**Molecular characteristics**

Six out of these seven patients (86%) shared the MYD88-L265P mutation, detected by q-PCR, in both neoplastic components (LPL and DLBCL). Case number 7 showed MYD88-L265P mutation in the LPL component while the DLBCL was wild-type (Table 2).

No alterations of BCL2, BCL6 or MYC genes were found in any case by FISH studies performed on paraffin-embedded-tissue.

IGH PCR studies (using Biomed primers) showed identical clonal peaks in both tumoral components in two cases, and different in four cases. In the remaining case (Case 5) the PCR technique was not evaluable.

The clonal peak differed in size between both components in three of the four cases diagnosed synchronously. Regarding cases initially diagnosed as LPL and developing a DLBCL during the course of the disease, one case showed the same clonal rearrangement in both components (Case 1), while in the other one the study was not informative (Case 5).

Next generation sequencing (NGS) was performed for both samples of every patient, using two different technical approaches and two different gene panels. In three patients at least one of the panels could be analyzed in both tumoral samples of the same patient, being in only two patients both methods informative. In the other cases one or both panels could be analyzed in at least one of the samples. In all LPL samples at least one of the two methods employed

---

**Fig 2.** Another LPL case evolving into DLBCL is shown. In figure A (H-E) and B (H-E) bone marrow biopsy with lymphoplasmacytic infiltration is seen. Cytoplasmic immunoglobulins displacing the nuclei to the periphery of the cell are clearly seen (B). In C (H-E), effacement of lymph node architecture by the proliferation of large cells with immunoblastic morphology is seen (D) (H-E). Scale bars of figures A is 2 mm, figure B is 100 μm, figure C is 1 mm and figure D is 50 μm.

https://doi.org/10.1371/journal.pone.0241634.g002
identified an additional alteration to MYD88-L265P mutation, while we obtained additional mutational data in just 3 DLBCL samples.

Apart from the MYD88-L265P mutation, other mutations were shared by the two tumoral components of the same patient in only one case (Case 1). Both the LPL and the DLBCL components of Case 1 showed ARID1A-V2041A mutation. Interestingly, a similar clonal rearrangement in both components was found. The DLBCL developed two years after the initial LPL diagnosis and showed an additional mutation in ARID1A-Q1818* gene.

Other genes mutated in the LPL component, in one case each, were CXCR4 (Case 2), NOTCH1 (Case 4), BAP1 (Case 5) or MYC (Case 7). Interestingly, a novel fusion between TBL1XR1-PIK3CA genes in a LPL case was also found (Case 6).
DLBCL cases showed additional mutations in *ARID1A, PIM1* and *CD79B* genes. Different mutations of *PIM1* gene were found in two different cases. No mutations of the *TP53* gene were found in any case. Allele frequencies around 50% were considered as polymorphisms.

**Discussion**

Progression of LPL into DLBCL has been estimated to occur in about 10% of the cases. We describe 7 patients diagnosed with both LPL and DLBCL, where clonal identity is supported by the presence of *MYD88-L265P* mutation (Cases 1–6), identical IGH rearrangements (Cases 1 and 3) or simultaneous presence in both components of additional mutational data (Case 1). Notwithstanding this common clonal origin, our series hints at divergent differentiation, as supported by the differences in the serial sample analysis of IGH, (3 cases showed different IGH rearrangements) and newly acquired somatic mutations.

Based on the one by one analysis of the cases we propose that there are at least three possible mechanisms of DLBCL development in LPL patients (Fig 3).

In our hands the largest subgroup of patients consisted of those with shared *MYD88* mutations in both lymphoma types, but harbored different IGH clonal peaks. In these cases a divergent clonal evolution from a common precursor neoplastic cell is proposed. Nevertheless, the appearance of two independent synchronous neoplasms cannot be definitively ruled out.

*MYD88* mutation has been found in healthy individuals as well as in peripheral blood mononuclear cells of patients with CNS lymphoma [14, 15], suggesting that this alteration might take place before IGH rearrangement. This data suggest that both tumors arose from cells harboring the *MYD88* mutation that further suffered either class switch recombination,

---

**Fig 3. Hypothesis of DLBCL development in patients with LPL.** First Hypothesis: Sequential mutation acquisition from LPL to DLBCL. Second hypothesis: Common origin with divergent evolution of either LPL and DLBCL neoplasms. Third hypothesis: A. Different lymphomas from a common stem cell or B. Different lymphomas from different stem cells.

https://doi.org/10.1371/journal.pone.0241634.g003
somatic hypermutation or ongoing \textit{IGH} mutations, leading to two partially-different independent tumoral clones [16]. \textit{MYD88-L265P} mutation has been considered a driver mutation in the development of WM, and in most cases of MGUS that evolve into WM [4].

Recently, biconality in WM patients has been documented [17, 18] and at least in 20% of WM patients two clonotypic sequences have been detected [19]. These data suggest that in some cases WM, rather than consisting of a monoclonal population, harbors two clonal populations evolved from a common ancestor [17, 18]. In the present study, this could explain that although LPL and DLBCL neoplastic cells of the same patient shared a \textit{MYD88} mutation, they had different \textit{IGH} rearrangement. Moreover, in most of our cases further somatic mutations in other genes were found exclusively in either the LPL or the DLBCL components. These findings, as well as previously reported data support our first hypothesis [20, 21]. Nevertheless, there are no biological models proving that \textit{MYD88} mutation takes place before \textit{IGH} rearrangement.

Durot \textit{et al.} [22] analyzed 77 patients with transformed LPL and found that most DLBCL showed extranodal involvement (91% of their cases). The most commonly involved extranodal sites were the bone marrow (18%), followed by bone (14%), spleen (14%) and central nervous system (13%). Moreover, most cases (82%) were of non-GC phenotype, like in our series, where all 7 DLBCL cases displayed a non-GC phenotype. It has been classically considered that the clonal lymphoplastic cell phenotype in WM corresponds to the late stage of B-cell differentiation and is derived from IgM-producing memory B cells that have undergone somatic hypermutation, but not isotype switching [16]. In general, it is worth mentioning that most ABC-DLBCL has not undergone class switching, and ABC-DLBCL express IgM more frequently than GCB-DLBCL [23, 24]. Moreover, it is well known that cases with \textit{MYD88-L265P} mutations are enriched in the ABC subtype [23, 24] and represent about 24% of the DLBCL cases. This percentage is high in DLBCL cases occurring in immune-privileged sites such as CNS (70%) and testes (74%), as well as in cutaneous leg-type DLBCL (54%), which are frequently of the ABC subtype [23, 24]. One of our DLBCL cases developed in CNS few months after the diagnosis of LPL in lymph node and bone marrow. This DLBCL also presented further somatic mutations not present in the LPL component and also frequently found in primary CNS DLBCL, such as \textit{PIM1} and \textit{CD79B} [15, 25]. On the other hand, Jimenez \textit{et al.} [26] identified \textit{CD79B} and \textit{PIM1} as one of the most frequently mutated genes in the transformation event in LPL cases or in the DLBCL component. Whether these two neoplasms took place as independent events although coincidentally in time or are originated from a common precursor cell harboring the \textit{MYD88} gene mutation cannot be elucidated. Furthermore, two cases in our series (50%) arose in lymph nodes (cases 2 and 6). The \textit{MYD88} mutation has been described in 17% of nodal DLBCL [27]. Moreover, both sporadic and familial cases of LPL have been associated with an increased risk of developing other hematological diseases, especially DLBCL [2, 28]. So, again, a coincidental, synchronous development of two independent hematological processes (LPL and DLBCL) cannot be easily be ruled out.

Interestingly, in some LPL cases other somatic mutations such as \textit{CXCR4} (Case 2), \textit{NOTCH1} (Case 4), \textit{BAP1} (Case 5) or \textit{MYC} (Case 7) and the novel fusion between \textit{TBL1XR1-PIK3CA} genes were also found (Case 6). These alterations in the DLBCL component of our cases could not be studied due to technical problems.

\textit{CXCR4} mutations are detected in 30–40% of LPL cases and in 9% of IgM MGUS [29, 30]. There are over 30 different mutations in the C-terminus of the \textit{CXCR4} gene identified in WM patients. The most common type is S338X nonsense mutation that causes increased activation of the Akt, ERK, BTK pathways resulting in enhanced migration, adhesion, growth and survival of cells in WM [29, 30]. Mutation in \textit{CXCR4} gene also confers primary resistance to Ibrutinib treatment [31, 32]. As far as we know, neither \textit{NOTCH1}, \textit{BAP1} or \textit{MYC} gene mutations
have been reported so far in LPL. Moreover, BAPI has not been previously found to be mutated in B-cell lymphomas.

In only two patients the DLBCL developed after the initial diagnosis of LPL, suggesting a progression/ transformation of the initial LPL (cases 1 and 5). Interestingly, in these two cases intense p53 expression was observed in both components, but no P53 gene mutations could be identified in the sequencing study. P53 mutation has been reported at diagnosis in 7.5% of LPL cases, being at lower frequency in IgM MGUS and associated to poor outcome [30]. It is highly correlated to deletion of 17p and to cases with higher number of genetic alterations [33]. Interestingly, Jiménez C et al. [26] identified p53 gene mutations by whole-exome sequencing studies in two patients at transformation or at progression, but not by the time of disease transformation of this last patient. They suggested that the transformed final clone did not originate in the intermediate subclone responsible from progression, but from a previous minor subclone that only grew after progression. Furthermore, they did not attribute p53 gene a key role in the transformation process.

In Case 1 the LPL and the DLBCL neoplastic cells shared both IGH rearrangements and further somatic mutations. ARID1A-V2041A mutation was shared by both tumoral matched samples (LPL and DLBCL) while a further mutation in the same gene (ARID1A-Q1818*) was exclusively found in the DLBCL component. ARID1A is a gene implicated in chromatin organization, being reported in 17% of LPL patients. These cases could represent a classic progression phenomenon, confirming some of the results previously published by Jiménez C et al. [26] after whole exome sequencing, showing the simultaneous presence of MYD88-L265P mutation in serial samples from MW progressing to LBCL. Based on their data, the authors suggest a common progenitor cell for both neoplasms, although following a branching model in the evolution process. Interestingly, all the patients they analyzed were initially diagnosed with LPL, with later development of the DLBCL after a median of 52 months. In our hands those cases suffered transformation after 35 and 12 months (median of 23.5 months), respectively.

On the other hand, in case 7 no MYD88 gene mutation could be identified in the DLBCL component, although it was present in the LPL clone diagnosed at the same time. Moreover, they showed different clonal IGH rearrangements and high intensity of p53 expression exclusively in the DLBCL component. Nevertheless, these data suggest the occurrence of a synchronous lymphoma with independent clonal origin, somehow similar to the case recently described by Talaulikar et al. [8]. On the other hand, lack of sensitivity of the employed techniques may have hindered the detection of other common molecular alterations in this case.

It is remarkable that in 4 out of 7 of our cases both LPL and DLBCL were diagnosed at the same time (cases 2, 3, 4 and 7). This frequency (57%) is much higher than previously reported (17%) [34] which could be due to reference bias, since we receive specimens from all over the country. Three of these cases showed different IGH rearrangements in either LPL or DLBCL counterpart samples. This data are in agreement with the case reported by Shimizu S et al. [35] who suggested a different clonal origin for both diseases after sequencing the CDR3 region.

Classically, it is believed that LPL without MYD88 mutation progresses to DLBCL with a higher probability than LPL cases with MYD88 mutation [36, 37]. Nevertheless, in our hands wild type MYD88 LPL cases are exceptional (only two documented cases in our archive) and none of them progressed into a more aggressive lymphoma.

In conclusion, our data point to the various progression scenarios in patients with metachronous or simultaneous occurrence of LPL and DLBCL. Some cases are consistent with tumoral progression, others (case 7) seem to represent a second malignancy, and while a significant group supports that a MYD88-mutated common progenitor gave rise to different clones characterized by divergent differentiation.
Supporting information

S1 Table. List of primers of the IGH gene rearrangement.  
(DOCX)

S2 Table. List of primers of the MYD88 gene.  
(DOCX)

S3 Table. List of probes of the custom B-cell lymphoma panel.  
(DOCX)

S4 Table. List of proteins analyzed in this series of patients.  
(DOCX)

Acknowledgments

We thank the CNIO (RD09/0076/00113), IDIVAL (RD09/0076/00076), BioB-HVS-BioBank (PT13/0010/0007) Tumour Banks, especially María Jesús Artiga and Laura Cereceda.

Author Contributions

Formal analysis: Rebeca Manso.

Investigation: Macarena Boiza-Sánchez, Rebeca Manso, Olga Balagué, Cristina Chamizo, Elham Askari, Rocío Nieves Salgado, Carlos Blas-López, Elena Aguirregoicoa-García, Javier Menárguez, Magdalena Adrados, Miguel Ángel Limeres-González, Miguel Angel Piris, Socorro María Rodríguez-Pinilla.

Methodology: Rebeca Manso, Olga Balagué, Cristina Chamizo, Socorro María Rodríguez-Pinilla.

Supervision: Carlos Santonja, Socorro María Rodríguez-Pinilla.

Validation: Socorro María Rodríguez-Pinilla.

Visualization: Rebeca Manso.

Writing – original draft: Macarena Boiza-Sánchez, Rebeca Manso, Socorro María Rodríguez-Pinilla.

Writing – review & editing: Olga Balagué, Cristina Chamizo, Elham Askari, Rocío Nieves Salgado, Carlos Blas-López, Elena Aguirregoicoa-García, Javier Menárguez, Carlos Santonja, Magdalena Adrados, Miguel Ángel Limeres-González, Miguel Ángel Piris, Socorro María Rodríguez-Pinilla.

References

1. Morton LM, Sampson JN, Cerhan JR, Turner JJ, Vajdic CM, Wang SS, et al. Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014; 2014(48):1–14. Epub 2014/09/01. lgu005 [pii] https://doi.org/10.1093/jncimonographs/lgu005 PMID: 25174022

2. Brandefors L, Kimby E, Lundqvist K, Melin B, Lindh J. Familial Waldenstrom’s macroglobulinemia and relation to immune defects, autoimmune diseases, and haematological malignancies–A population-based study from northern Sweden. Acta Oncol. 2016; 55(1):91–8. Epub 2015/11/13. https://doi.org/10.3109/0284186X.2015.1096019 PMID: 26559865

3. Fang H, Kapoor P, Gonsalves WI, Frederick LA, Viswanatha D, Howard MT, et al. Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic
20. Treon SP, Xu L, Liu X, Hunter ZR, Yang G, Castillo JJ. Genomic Landscape of Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018; 32(5):745–52. Epub 2018/09/08. S0889-8588(18)30729-9 [pii]. https://doi.org/10.1016/j.hoc.2018.05.003 PMID: 30190014

5. Rosenquist R, Rosenwald A, Du MQ, Gaidano G, Groenen P, Wotherspoon A, et al. Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond. Haematologica. 2016; 101(9):1002–9. Epub 2016/09/02. haematol.2015.134510 [pii] https://doi.org/10.3324/haematol.2015.134510 PMID: 27582569

6. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127 (20):2391–405. Epub 2016/04/14. blood-2016-03-643544 [pii] https://doi.org/10.1182/blood-2016-03-643544 PMID: 27069254

7. Jiménez C, Alonso-Alvarez S, Alcoceba M, Ordoñez GR, Garcia-Alvarez M, Prieto-Conde MI, et al. From Waldenström’s macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation. Blood Cancer J. 2017; 7(8):e591. Epub 2017/08/26. bcj201772 [pii] https://doi.org/10.1038/bcj.2017.72 PMID: 28841204

8. Talaulikar D, Biscoe A, Lim JH, Gibson J, Arthur C, Mackinlay N, et al. Genetic analysis of Diffuse Large B-Cell Lymphoma occurring in cases with antecedent Waldenström Macroglobulinemia reveals different patterns of clonal evolution. Br J Haematol. 2019; 185(4):767–70. Epub 2018/10/20. https://doi.org/10.1111/bjh.15610 PMID: 30338255

9. Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition). IARC: Lyon 2017. 2017.

10. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003; 17(12):2257–317. Epub 2003/12/13. https://doi.org/10.1038/sj.bj.6900139 PMID: 14671650

11. Groenen PJ, Langerak AW, von Dongen JJ, van Kriekeren JH. Pitfalls in TCR gene clonality testing: teaching cases. J Hematopathol. 2008; 1(2):97–109. Epub 2008/09/12. bcj201772 [pii] https://doi.org/10.1038/bcj.2008.9 PMID: 19669208

12. Jiménez C, Chilón Mdcl C, Balanzateguí A, Puig N, Sebastián E, Alcoceba M, et al. Detection of MYD88 L265P mutation by real-time allelic-specific oligonucleotide polymerase chain reaction. Appl Immunohistochem Mol Morphol. 2017; 22(10):768–73. Epub 2014/07/06. https://doi.org/10.1097/PAI.0000000000000220 PMID: 24992174

13. Franco F, Gonzalez-Rincon J, Lavermia J, Garcia JF, Martin P, Bellas C, et al. Mutational profile of primary breast diffuse large B-cell lymphoma. Oncotarget. 2017; 8(61):102888–97. Epub 2017/12/22. https://doi.org/10.18632/oncotarget.21986 PMID: 29262531

14. Hattori K, Sakata-Yanagimoto M, Kusakabe M, Nanmoku T, Suehara Y, Matsuoka R, et al. Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma. Cancer Sci. 2019; 110(1):401–7. Epub 2018/10/26. CAS13848 [pii] https://doi.org/10.1111/cas.13848 PMID: 30353605

15. Fukumura K, Kawazu M, Kojima S, Ueno T, Sai E, Soda M, et al. Genomic characterization of primary central nervous system lymphoma. Acta Neuropathol. 2016; 131(6):865–75. Epub 2016/01/14. https://doi.org/10.1007/s00401-016-1536-2 [pii] 10.1007/s00401-016-1536-2 PMID: 26577737

16. Growková K, Kryukova E, Kufová Z, Filipová J, Sevciková T, Rihová L, et al. Waldenström’s macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection. Eur J Haematol. 2017; 99(6):469–78. Epub 2017/09/09. https://doi.org/10.1111/ejh.12959 PMID: 2886236

17. Boneveld L, Virella G, Wang AC. Evidence for the biclonal nature of a Waldenström’s macroglobulinemia. Clin Chim Acta. 1985; 146(1):53–63. Epub 1985/02/28. 0009-8981(85)90123-8 [pii] https://doi.org/10.1016/0009-8981(85)90123-8 PMID: 3921286

18. Schulz R, David D, Farkas DH, Crisan D. Molecular Analysis in a Patient With Waldenström’s Macroglobulinemia Reveals a Rare Case of Bclonality. Mol Diagn. 1996; 1(3):159–66. Epub 1996/09/01. S1084859296000124 [pii] https://doi.org/10.1054/mdi.1996.00125 PMID: 10462556

19. Ciric B, VanKeulen V, Rodriguez M, Kyle RA, Gertz MA, Pease LR. Clonal evolution in Waldenström macroglobulinemia highlights functional role of B-cell receptor. Blood. 2001; 97(1):321–3. Epub 2001/01/03. https://doi.org/10.1182/blood.v97.1.321 PMID: 11133777

20. Treon SP, Xu L, Hunter Z. MYD88 Mutations and Response to Ibrutinib in Waldenström’s Macroglobulinaemia. N Engl J Med. 2015; 373(6):584–6. Epub 2015/08/06. https://doi.org/10.1056/NEJMc1506192 PMID: 26244327
21. Prieto-Torres L, Trascasa A, Manso R, Machan S, Cieza-Diaz D, Olmedilla G, et al. Two independent consecutive lymphoma cases carry an identical MYD88 mutation but differ in their IGHV rearrangement. Br J Haematol. 2020. Epub 2020/06/25. https://doi.org/10.1111/bjh.16917 PMID: 32578872

22. Durot E, Tomowiac K, Michallet AS, Dupuis J, Hivert B, Lepretre S, et al. Transformed Waldenström macroglobulinemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO). Br J Haematol. 2017; 179(3):439–48. Epub 2017/08/05. https://doi.org/10.1111/bjh.14881 PMID: 28770576

23. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018; 378(15):1396–407. Epub 2018/04/12. https://doi.org/10.1056/NEJMoa1801445 PMID: 29641966

24. Yu X, Li W, Deng Q, Li L, Hsi ED, Young KH, et al. MYD88 L265P Mutation in Lymphoid Malignancies. Cancer Res. 2018; 78(10):2457–62. Epub 2018/04/29. 0008-5472.CAN-18-0215 [pii] https://doi.org/10.1158/0008-5472.CAN-18-0215 PMID: 29703722

25. Vater I, Montesinos-Rongen M, Schlesner M, Haake A, Purschke F, Sprute R, et al. The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. Leukemia. 2015; 29(3):677–85. Epub 2014/09/06. leu2014 264 [pii] https://doi.org/10.1038/leu.2014.264 PMID: 25158415

26. Jiménez C, Alonso-Alvarez S, Alcoceba M, Ordoñez GR, García-Alvarez M, Prieto-Conde MI, et al. From Waldenström’s macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation. Blood Cancer J. 2017; 7(8):e591. Epub 2017/08/26. bcj201772 [pii] https://doi.org/10.1038/bcj.2017.72 PMID: 28841204

27. Vermaat JS, Somers SF, de Wreede LC, Kraan W, de Groen RAL, Schrader AMR, et al. MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis. Haematologica. 2020; 105(2):424–34. Epub 2019/05/28. haematol.2018.214122 [pii] 1050424 [pii] https://doi.org/10.3324/haematol.2018.214122 PMID: 31123031

28. Morra E, Varettoni M, Tedeschi A, Arcaini L, Ricci F, Pascutto C, et al. Associated cancers in Waldenström macroglobulinemia: clues for common genetic predisposition. Clin Lymphoma Myeloma Leuk. 2013; 13(6):700–3. Epub 2013/09/28. S2152-2650(13)00225-5 [pii] https://doi.org/10.1016/j.clml.2013.05.008 PMID: 24070824

29. Poulain S, Roumier C, Venet-Caillaud A, Figsec M, Herbaux C, Marot G, et al. Genetic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia. Clin Cancer Res. 2016; 22(6):1480–8. Epub 2015/10/23. 1078-0432.CCR-15-0646 [pii] https://doi.org/10.1158/1078-0432.CCR-15-0646 PMID: 26490317

30. Varettoni M, Zibellini S, Defrancesco I, Ferretti VV, Rizzo E, Malcovati L, et al. Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. Haematologica. 2017; 102(12):2077–85. Epub 2017/10/07. haematol.2017.172718 [pii] 1012077 [pii] https://doi.org/10.3324/haematol.2017.172718 PMID: 28983055

31. Xu L, Tsakmaklis N, Yang G, Chen JG, Liu X, Demos M, et al. Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. Blood. 2017; 129(18):2519–25. Epub 2017/02/27. blood2017 655 [pii] https://doi.org/10.1182/blood-2017-01-761725 PMID: 28235842

32. Poulain S, Roumier C, Bertrand E, Renneville A, Caillault-Venet A, Doye E, et al. TP53 Mutation and Its Prognostic Significance in Waldenström Macroglobulinemia. Clin Cancer Res. 2018; 24(20):6325–35. Epub 2017/10/09. doi: https://doi.org/10.1158/1078-0432.CCR-15-0646 PMID: 26490317

33. Treon SP, Gustine J, Xu L, Manning RJ, Tsakmaklis N, Demos M, et al. MYD88 wild-type Waldenström Macroglobulinemia: differential diagnosis, risk of histological transformation, and overall survival. Br J Haematol. 2018; 180(3):374–80. Epub 2017/11/29. https://doi.org/10.1111/bjh.15049 PMID: 29181840

34. Zanwar S, Abeykoon JP, Durot E, King R, Perez Burbano GE, Kumar S, et al. Impact of MYD88(L265P) mutation status on histological transformation of Waldenström Macroglobulinemia. Am J Hematol. 2020; 95(3):274–81. Epub 2019/12/10. https://doi.org/10.1002/ajh.25697 PMID: 31814157